Sun Pharma. News

Intimation regarding order passed by Statutory Authority

Intimation regarding Order passed by Statutory Authority

Intimation regarding loss of share certificate

The political unrest and violence in Bangladesh are posing significant challenges for Indian pharmaceutical exporters, leading to stranded funds and concerns over financial stability. This situation threatens to impact medicine availability and healthcare services in Bangladesh. Despite the market's growth potential, many Indian companies are now hesitant to supply without advance payments, emphasising the importance of risk management in this unpredictable scenario.

Intimation regarding order passed by Statutory Authority

Intimation of Schedule of Analyst/Institutional Investor Meeting

On Wednesday, the Nifty50 reached a new all-time high of 25,104, surpassing its previous peak of 25,078 after 18 trading sessions. The Sensex is just 143 points away from its fresh high of 82,129. By 11:50 am, the Nifty50 was up 86 points (0.35%), and the Sensex had risen 273 points (0.33%) to 81,986.

Pharma stocks have gained investor interest as the Nifty Pharma index reaches new highs. Amid economic uncertainties, defensive sectors like pharma offer minimal risk. Notable picks include Lupin, Sun Pharma, and Dr Reddy's. The sector saw significant foreign inflows, driven by the performance of the generic drug Revlimid.

Canadian billionaire Prem Watsa's Fairfax Group and Bain Capital are in competition for a buyout of Farmson Basic Drugs, a leading API maker in India valued at ₹4,000 crore. Founded in 1969, Farmson is a major paracetamol manufacturer with a revenue of ₹1,750 crore in FY24. The company's concentrated focus on paracetamol production is a strength, but limited R&D poses challenges for diversification.

Intimation regarding ESG Overview for FY 2023-24

Intimation regarding order passed by Statutory Authority

The Sensex and Nifty50 rose on Monday, buoyed by gains in financial and IT stocks after U.S. Federal Reserve Chair Jerome Powell hinted at upcoming interest rate cuts. Major gainers included Tech Mahindra and TCS, while sectors such as IT and Financial Services saw growth. Conversely, FMCG and Pharma sectors experienced declines.

Sun Pharmaceutical Industries Ltd., incorporated in the year 1993, is a Large Cap company (having a market cap of Rs 426061.91 Crore) operating in Pharmaceuticals sector.

Last week, the Nifty index exhibited a choppy but positive trend, with potential gains towards 25,100-25,200. Analysts noted important support levels and recommended buying opportunities during minor dips. Stocks such as ICICI Bank, Nykaa, Sun Pharma, and Bajaj Auto showed positive momentum. Investors were advised to cautiously maintain and seek long positions.

Intimation regarding order passed by statutory authority

Sun Pharma introduces a novel treatment, STARIZO in India for acute bacterial skin and skin structure infections.

The BSE Sensex was trading 42 points, or 0.05%, lower at 81,009. The Nifty50 was down 7 points, or 0.03%, trading at 24,803 around 9:19 am.

Intimation regarding issuance of duplicate share certificates

The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 20, 2024 for Raksha Sudhir Valia

The domestic pharmaceutical retail market saw an impressive 11% growth in July, attributed to increased sales of anti-infectives and pain relief due to rising flu and viral infections. Antibiotic Augmentin led sales at Rs 72 crore and topped the charts. Overall market valued at Rs 2,22,906 crore, showing 7 per cent growth in June. Sun Pharma maintained a top position, with Indian companies growing at 11.4 per cent and MNCs at 10.2 per cent in July. Analysts predict a 10 per cent growth driven by demand for acute therapies like anti-infectives.

Intimation regarding Loss of Share Certificate

Intimation regarding loss of share certificate

Intimation regarding the agreement for investment.

Intimation of Schedule of Analyst/Institutional Investor Meeting

The Jhunjhunwala family's wealth in listed firms, which surpassed ₹50,000 crore for the first time in the March quarter, declined by nearly 8% to ₹47,053 crore by the end of the June quarter. Stocks like Titan, Crisil, and Sun Pharma Advanced Research fell between 10% and 35% during this period.

Intimation regarding loss of share certificate.

FMCG and pharma stocks have surged up to 23% over the last month, proving their defensive strength, while the Nifty50 has declined amid high volatility and a 27% rise in the India VIX. The Nifty FMCG and Pharma indices have gained 8% and 7.7%, respectively, versus a 0.11% drop in the broader Nifty.

SPIL Q1FY25 Earning Call Trascript

Intimation of Schedule of Analyst/Institutional Investor Meeting

Scrutinizer''s Consolidated Report and Voting Results for 32nd AGM

The pharma major declined after reaching a high of Rs 1,638 on April 5, 2024. It found support above the 200-day EMA on the daily charts and the 40-week EMA on the weekly charts. Bouncing back from this support, the stock broke out from its April swing high and reached a new record above 1,700. The Sensex stock hit a record high of Rs 1,758 on August 5, 2024.

Outcome of 32nd Annual General Meeting

Trading on Monday saw Tata Motors and ONGC shares fall by 5%, causing the Nifty 50 index to drop by 3%. Shares of Hindalco, Mahindra & Mahindra, and Tata Steel also declined. Britannia, Sun Pharma, and a few other stocks managed gains. The market was influenced by global economic concerns and potential US recession indicators.

Experts advised investors to exercise caution amid market instability. Nifty's potential downturn was linked to maintaining positions below 24,800 and VIX levels. Key stocks such as Nykaa, HDFC Bank, and Sun Pharma were highlighted. Important support and resistance levels were noted for Nifty, indicating potential market movements and recommended buying strategies.

Leqselvi is used for the treatment of alopecia areata, an autoimmune disease that leads to hair loss, and was approved by the US Food and Drug Administration (USFDA) last week. Sun Pharma has been making preparations for months to launch the drug in July, but an injunction motion by the American drugmaker lncyte Corporation in the US District Court for the District of New Jersey has put the brakes on the launch.

Intimation regarding Loss of Share Certificate

Jefferies has maintained a buy rating on ITC with a target price of Rs 585. The 3% growth in cigarette business volume met expectations, and stable taxation suggests continued momentum in the coming quarters. However, other segments fell short in terms of revenues and margins.

Q1FY25 - Investor Call audio recording

Sun Pharma reported a 40% year-on-year (YoY) jump in net profit to Rs 2,836 crore in Q1FY25 led by higher sales growth in domestic formulation, emerging markets and global specialty portfolio.

Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.